Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Barbara Petzold"'
Autor:
Paul Chaplin, Amanda Handley, Petra Rapp, Lyn Mateo, Niels Wulff, Herwig Kollaritsch, Alfred von Krempelhuber, Rolf Pokorny, Jens Vollmar, Henriette Siersbol, Barbara Petzold
Publikováno v:
Vaccine. 28:1209-1216
IMVAMUNE is a Modified Vaccinia Ankara (MVA)-based virus that is being developed as a safer 3rd generation smallpox vaccine. In order to determine the optimal dose for further development, a double-blind, randomized Phase II trial was performed testi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c06a0900182a5c498fabf3978016b0
https://doi.org/10.1016/j.vaccine.2009.11.030
https://doi.org/10.1016/j.vaccine.2009.11.030
Autor:
Vanessa Hülsemann, Lynette King, Jens Vollmar, Maria Tzatzaris, Karl M. Eckl, Niels Wulff, Luis Mateo, Barbara Petzold, Bernd Schlereth, Karin Merkl, Amanda Handley, T. Thomsen, Paul Chaplin, Nathaly Arndtz
Publikováno v:
Vaccine. 24:2065-2070
A Phase I trial was performed to investigate the safety and immunogenicity of the third generation smallpox vaccine MVA-BN (IMVAMUNE), a highly attenuated clone derived from the Modified Vaccinia Virus Ankara strain 571, in naive and pre-immunized su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ce24684afe2276d0082c9a53d7468d
https://doi.org/10.1016/j.vaccine.2005.11.022
https://doi.org/10.1016/j.vaccine.2005.11.022
Autor:
Ellen Harrer, Michael Bäuerle, Barbara Ferstl, Paul Chaplin, Barbara Petzold, Luis Mateo, Amanda Handley, Maria Tzatzaris, Jens Vollmar, Silke Bergmann, Marion Rittmaier, Kathrin Eismann, Sandra Müller, Joachim R Kalden, Bernd Spriewald, Dieter Willbold, Thomas Harrer
Publikováno v:
Antiviral therapy. 10(2)
The safety and immunogenicity of an HIV-1 nef-expressing modified vaccinia virus Ankara (MVA) was investigated in 14 HIV-1-positive patients (CD4 >400/μl) on highly active antiretroviral therapy (HAART). Patients were vaccinated at weeks 0, 4 and 16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2cfb56dbed6b5875ca8237bd77da42d
https://pubmed.ncbi.nlm.nih.gov/15865223
https://pubmed.ncbi.nlm.nih.gov/15865223
Autor:
Cedrik M. Britten, Alexander Enk, Nathaly Arndtz, Stephan N. Wagner, Paul Chaplin, Thomas Wölfel, Gerold Schuler, Jost Metz, Tolga A. Sagban, Thilo Jakob, Bernd Weigle, Luis Mateo, Gerd Sutter, Beatrice Schuler-Thurner, Hans A. Lehr, Barbara Petzold, Rüdiger Hein, Burkhard Schmidt, Ingo Drexler, Marc Schmitz, Christoph Huber, Ulrike Siepmann, Ralf G. Meyer, Helga Bernhard
Publikováno v:
Cancer immunology, immunotherapy : CII. 54(5)
A significant percentage of patients with stage II melanomas suffer a relapse after surgery and therefore need the development of adjuvant therapies. In the study reported here, safety and immunological response were analyzed after vaccination in an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950c3ce5f30d8018801a67a23e35fa7e
https://pubmed.ncbi.nlm.nih.gov/15627214
https://pubmed.ncbi.nlm.nih.gov/15627214